蚌埠医学院学报
蚌埠醫學院學報
방부의학원학보
ACTA ACADEMIAE MEDICINAE BENGBU
2014年
9期
1185-1186
,共2页
马子东%冯朋%周益文%高晓东
馬子東%馮朋%週益文%高曉東
마자동%풍붕%주익문%고효동
乙肝病毒%母婴传播%乙肝免疫球蛋白
乙肝病毒%母嬰傳播%乙肝免疫毬蛋白
을간병독%모영전파%을간면역구단백
Hepatitis B virus%mother-to-infant transmission%Hepatitis B immunoglobulin
目的:采用乙型肝炎(乙肝)免疫球蛋白( HBIG)对乙肝病毒( HBV)阻断母婴传播,探讨其效果及安全性。方法:110例确诊为HBV携带者的产妇按照自愿原则均分为2组,观察组孕28周注射HBIG,对照组不注射,比较新生儿乙肝表面抗原( HBsAg)的阳性检出率,以及所有新生儿经过6个月的治疗乙肝表面抗体( HBsAb)的检出率。结果:经过阻断治疗,观察组患者所产新生儿的HBsAg阳性检出率为9.09%,对照组患者所产新生儿的HBsAg阳性检出率为34.55%,差异有统计学意义(P<0.01)。所有新生儿中经过6个月的治疗后HBsAb检出率为64.55%,明显优于出生1个月的22.72%(P<0.01),并且在治疗期间孕妇及新生儿均未出现不良反应。结论:HBIG在阻断HBV在母婴之间的传播具有非常显著的疗效,并且在安全性方面也有一定的保障,可以应用于临床。
目的:採用乙型肝炎(乙肝)免疫毬蛋白( HBIG)對乙肝病毒( HBV)阻斷母嬰傳播,探討其效果及安全性。方法:110例確診為HBV攜帶者的產婦按照自願原則均分為2組,觀察組孕28週註射HBIG,對照組不註射,比較新生兒乙肝錶麵抗原( HBsAg)的暘性檢齣率,以及所有新生兒經過6箇月的治療乙肝錶麵抗體( HBsAb)的檢齣率。結果:經過阻斷治療,觀察組患者所產新生兒的HBsAg暘性檢齣率為9.09%,對照組患者所產新生兒的HBsAg暘性檢齣率為34.55%,差異有統計學意義(P<0.01)。所有新生兒中經過6箇月的治療後HBsAb檢齣率為64.55%,明顯優于齣生1箇月的22.72%(P<0.01),併且在治療期間孕婦及新生兒均未齣現不良反應。結論:HBIG在阻斷HBV在母嬰之間的傳播具有非常顯著的療效,併且在安全性方麵也有一定的保障,可以應用于臨床。
목적:채용을형간염(을간)면역구단백( HBIG)대을간병독( HBV)조단모영전파,탐토기효과급안전성。방법:110례학진위HBV휴대자적산부안조자원원칙균분위2조,관찰조잉28주주사HBIG,대조조불주사,비교신생인을간표면항원( HBsAg)적양성검출솔,이급소유신생인경과6개월적치료을간표면항체( HBsAb)적검출솔。결과:경과조단치료,관찰조환자소산신생인적HBsAg양성검출솔위9.09%,대조조환자소산신생인적HBsAg양성검출솔위34.55%,차이유통계학의의(P<0.01)。소유신생인중경과6개월적치료후HBsAb검출솔위64.55%,명현우우출생1개월적22.72%(P<0.01),병차재치료기간잉부급신생인균미출현불량반응。결론:HBIG재조단HBV재모영지간적전파구유비상현저적료효,병차재안전성방면야유일정적보장,가이응용우림상。
Objective:To discuss the efficacy and safety of hepatitis B immunoglobulin(HBIG) in blocking the hepatitis B virus ( HBV) transmission in mother-to-infant. Methods:One hundred and ten HBV puerperal carriers were divided into the observation group and control group on voluntary basis(55 cases each group). The observation group were injected with HBIG at 28 gestational weeks,and the control group did not be injected. The detection rates of hepatitis B surface antigen( HBsAg) in newborns and hepatitis B surface antibody( HBsAb) in newborns after 6-month treatment between two groups were compared. Results:The detection rates of newborns HBsAg in observation group and control group were 9. 09% and 34. 55%,respectively,the difference of which was statistical significance(P<0. 01). The detection rate of HBsAb in newborns after 6-month treatment(64. 55%) was significantly better than that in 1-month newborns(22. 72%) (P <0. 01),and there were not significant adverse reactions in pregnant woman and newborn. Conclusions:HBIG in blocking the HBV transmission in mother-to-infant is effective and safe,which can be applied in clinic.